Amyloid-related imaging abnormalities

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC

Amyloid-related imaging abnormalities
File:Amyloid related imaging abnormalities.jpg
Synonyms	N/A
Pronounce	N/A
Specialty	N/A
Symptoms	Headache, confusion, seizures, focal neurological deficits
Complications	Cerebral edema, microhemorrhages
Onset	Typically after initiation of monoclonal antibody therapy for Alzheimer's disease
Duration	Variable, often resolves with discontinuation of therapy
Types	N/A
Causes	Monoclonal antibody treatment targeting amyloid beta
Risks	Apolipoprotein E ε4 allele, high dose of therapy
Diagnosis	MRI
Differential diagnosis	Cerebral amyloid angiopathy, stroke, multiple sclerosis
Prevention	N/A
Treatment	Discontinuation or adjustment of monoclonal antibody therapy
Medication	N/A
Prognosis	Generally good with appropriate management
Frequency	Occurs in a subset of patients receiving monoclonal antibody therapy
Deaths	N/A

Amyloid-related imaging abnormalities (ARIA) are a group of side effects observed in some patients undergoing magnetic resonance imaging (MRI) after receiving certain treatments for Alzheimer's disease. These abnormalities are associated with the use of amyloid-targeting therapies, including monoclonal antibodies designed to reduce amyloid beta plaques in the brain, a hallmark of Alzheimer's disease. ARIA is divided into two main types: ARIA-E (edema) and ARIA-H (hemorrhage).

Types of ARIA

ARIA-E (Edema)

ARIA-E refers to vasogenic edema, a type of brain swelling caused by the leakage of fluid from blood vessels into the brain's interstitial spaces. It is detected on MRI scans as hyperintensities in T2-weighted fluid-attenuated inversion recovery (FLAIR) sequences. Patients with ARIA-E may be asymptomatic or present with neurological symptoms such as headache, confusion, dizziness, and, in severe cases, seizures.

ARIA-H (Hemorrhage)

ARIA-H encompasses microhemorrhages and superficial siderosis. Microhemorrhages are small points of bleeding in the brain, while superficial siderosis involves the deposition of hemosiderin (a blood breakdown product) on the brain's surface. ARIA-H is typically detected on gradient echo (GRE) or susceptibility-weighted imaging (SWI) sequences of MRI scans. Like ARIA-E, ARIA-H can be asymptomatic or associated with neurological symptoms.

Risk Factors

Factors that may increase the risk of developing ARIA include the presence of the apolipoprotein E (APOE) ε4 allele, a genetic variant associated with a higher risk of Alzheimer's disease, and the use of anticoagulant medication. The incidence and severity of ARIA may also vary depending on the dosage and type of amyloid-targeting therapy.

Management

The management of ARIA involves regular monitoring through MRI scans, especially during the initial phases of amyloid-targeting therapy. In symptomatic cases or when ARIA is severe, temporary suspension or discontinuation of the therapy may be necessary. The use of corticosteroids to reduce inflammation and edema has been explored, but there is no standardized treatment protocol for ARIA.

Implications for Alzheimer's Disease Treatment

The occurrence of ARIA poses challenges for the development and clinical use of amyloid-targeting therapies in Alzheimer's disease. While these therapies hold promise for reducing amyloid plaques and potentially slowing disease progression, the risk of ARIA necessitates careful patient selection, monitoring, and management strategies. Ongoing research aims to better understand the mechanisms underlying ARIA, identify patients at higher risk, and develop approaches to minimize its occurrence and impact.